LIPO-Liposome Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome

LIPO 0.309

0.0%

Dec 5 11:59 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pete NY who wrote (793)	9/1/1999 6:18:00 PM
From: G-MAN	Read Replies (2) of 900

Does anyone care to comment on the following that was posted on the Raging Bull board for LIPO. Question on Avalon report: Avalon argues that, while Evacet is "statistically significant" at low doses, it has yet to be demonstrated that Evacet's effectiveness is "clinically significant" at high doses. While the Phase III trials showed statistically significant reduction in cardiotoxicity at low doses, Avalon cites the Phase II trials as showing cardiotoxicity at high doses. Since ODAC on 9-16 will be interested in what is clinically significant, Avalon "doubts" Evacet will be approved. Any informed responses to this?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next